These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 23904283)

  • 1. Influence of ovarian manipulation on reproductive endocrinology in polycystic ovarian syndrome and regularly cycling women.
    Hendriks ML; König T; Soleman RS; Korsen T; Schats R; Hompes PG; Homburg R; Lambalk CB
    Eur J Endocrinol; 2013 Oct; 169(4):503-10. PubMed ID: 23904283
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mid-follicular phase pulses of inhibin B are absent in polycystic ovarian syndrome and are initiated by successful laparoscopic ovarian diathermy: a possible mechanism regulating emergence of the dominant follicle.
    Lockwood GM; Muttukrishna S; Groome NP; Matthews DR; Ledger WL
    J Clin Endocrinol Metab; 1998 May; 83(5):1730-5. PubMed ID: 9589683
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Short-term changes in hormonal profiles after laparoscopic ovarian laser evaporation compared with diagnostic laparoscopy for PCOS.
    Hendriks ML; König T; Korsen T; Melgers I; Dekker J; Mijatovic V; Schats R; Hompes PG; Homburg R; Kaaijk EM; Twisk JW; Lambalk CB
    Hum Reprod; 2014 Nov; 29(11):2544-52. PubMed ID: 25267790
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serum anti-Müllerian hormone and inhibin B concentrations are not useful predictors of ovarian response during ovulation induction treatment with recombinant follicle-stimulating hormone in women with polycystic ovary syndrome.
    Lie Fong S; Schipper I; de Jong FH; Themmen AP; Visser JA; Laven JS
    Fertil Steril; 2011 Aug; 96(2):459-63. PubMed ID: 21719005
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gonadotropin-releasing hormone (GnRH) analog suppression renders polycystic ovarian disease patients more susceptible to ovulation induction with pulsatile GnRH.
    Filicori M; Campaniello E; Michelacci L; Pareschi A; Ferrari P; Bolelli G; Flamigni C
    J Clin Endocrinol Metab; 1988 Feb; 66(2):327-33. PubMed ID: 3123511
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Müllerian-inhibiting substance reflects ovarian findings in women with polycystic ovary syndrome better than does inhibin B.
    Chu MC; Carmina E; Wang J; Lobo RA
    Fertil Steril; 2005 Dec; 84(6):1685-8. PubMed ID: 16359965
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Determinants of abnormal gonadotropin secretion in clinically defined women with polycystic ovary syndrome.
    Taylor AE; McCourt B; Martin KA; Anderson EJ; Adams JM; Schoenfeld D; Hall JE
    J Clin Endocrinol Metab; 1997 Jul; 82(7):2248-56. PubMed ID: 9215302
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inverse relationship between luteinizing hormone and body mass index in polycystic ovarian syndrome: investigation of hypothalamic and pituitary contributions.
    Pagán YL; Srouji SS; Jimenez Y; Emerson A; Gill S; Hall JE
    J Clin Endocrinol Metab; 2006 Apr; 91(4):1309-16. PubMed ID: 16434454
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Polycystic ovarian syndrome: evidence that flutamide restores sensitivity of the gonadotropin-releasing hormone pulse generator to inhibition by estradiol and progesterone.
    Eagleson CA; Gingrich MB; Pastor CL; Arora TK; Burt CM; Evans WS; Marshall JC
    J Clin Endocrinol Metab; 2000 Nov; 85(11):4047-52. PubMed ID: 11095431
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recovery of hormone secretion after chronic gonadotropin-releasing hormone agonist administration in women with polycystic ovarian disease.
    de Ziegler D; Steingold K; Cedars M; Lu JK; Meldrum DR; Judd HL; Chang RJ
    J Clin Endocrinol Metab; 1989 Jun; 68(6):1111-7. PubMed ID: 2524501
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Serum levels of anti-muller hormone in women with polycystic ovary syndrome and healthy women of reproductive age].
    Parahuleva N; Pehlivanov B; Orbecova M; Deneva T; Uchikova E
    Akush Ginekol (Sofiia); 2013; 52 Suppl 1():16-23. PubMed ID: 24294740
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serum anti-Müllerian hormone levels remain high until late reproductive age and decrease during metformin therapy in women with polycystic ovary syndrome.
    Piltonen T; Morin-Papunen L; Koivunen R; Perheentupa A; Ruokonen A; Tapanainen JS
    Hum Reprod; 2005 Jul; 20(7):1820-6. PubMed ID: 15802325
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Specific factors predict the response to pulsatile gonadotropin-releasing hormone therapy in polycystic ovarian syndrome.
    Gill S; Taylor AE; Martin KA; Welt CK; Adams JM; Hall JE
    J Clin Endocrinol Metab; 2001 Jun; 86(6):2428-36. PubMed ID: 11397835
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of ovarian function in 35-40-year-old women with polycystic ovary syndrome.
    de Guevara AL; Crisosto N; Echiburú B; Preisler J; Vantman N; Bollmann J; Pérez-Bravo F; Sir-Petermann T
    Eur J Obstet Gynecol Reprod Biol; 2013 Sep; 170(1):165-70. PubMed ID: 23845170
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effects of ovarian wedge resection on circulating gonadotropin and ovarian steroid levels in patients with polycystic ovary syndrome.
    Judd HL; Rigg LA; Anderson DC; Yen SS
    J Clin Endocrinol Metab; 1976 Aug; 43(2):347-55. PubMed ID: 950366
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Disruption of follicular maturation and delay of ovulation after administration of the antiprogesterone RU486.
    Liu JH; Garzo G; Morris S; Stuenkel C; Ulmann A; Yen SS
    J Clin Endocrinol Metab; 1987 Dec; 65(6):1135-40. PubMed ID: 2824550
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inappropriate gonadotropin secretion in polycystic ovary syndrome: influence of adiposity.
    Arroyo A; Laughlin GA; Morales AJ; Yen SS
    J Clin Endocrinol Metab; 1997 Nov; 82(11):3728-33. PubMed ID: 9360532
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Anti-Mullerian hormone in the major phenotypes of polycystic ovary syndrome].
    Parahuleva N; Pehlivanov B; Orbecova M; Uchikova E; Ivancheva H
    Akush Ginekol (Sofiia); 2014; 53(5):22-7. PubMed ID: 25558667
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Loss of LH-induced down-regulation of anti-Müllerian hormone receptor expression may contribute to anovulation in women with polycystic ovary syndrome.
    Pierre A; Peigné M; Grynberg M; Arouche N; Taieb J; Hesters L; Gonzalès J; Picard JY; Dewailly D; Fanchin R; Catteau-Jonard S; di Clemente N
    Hum Reprod; 2013 Mar; 28(3):762-9. PubMed ID: 23321213
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Predictive markers for the FSH sensitivity of women with polycystic ovarian syndrome.
    Köninger A; Sauter L; Edimiris P; Kasimir-Bauer S; Kimmig R; Strowitzki T; Schmidt B
    Hum Reprod; 2014 Mar; 29(3):518-24. PubMed ID: 24419495
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.